NYX 2925

Drug Profile

NYX 2925

Alternative Names: NYX-2925

Latest Information Update: 24 Nov 2016

Price : $50

At a glance

  • Originator Aptinyx
  • Class Small molecules
  • Mechanism of Action NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Neuropathic pain
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neurological disorders
  • Preclinical Neuropathic pain

Most Recent Events

  • 26 Sep 2016 Pharmacodynamics and pharmacokinetics data from a preclinical study in Neurological indications presented at the 16th World Congress on Pain (WCP-2016)
  • 26 Sep 2016 Pharmacodynamics data from a preclinical study in Neuropathic pain presented at the 16th World Congress on Pain (WCP-2016)
  • 15 Sep 2016 NYX 2925 receives Fast Track designation for Neuropathic pain [PO] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top